India Next Generation Sequencing Market Size, Share and Trends 2026 to 2035

The India next generation sequencing market size was estimated at USD 850 million in 2025 and is projected to be gain around USD 4922.45 million by 2035, growing at a CAGR of 19.20% from 2026 to 2035. The market is driven by the increase in cancer and rare disease cases, decreasing sequencing costs, the growth of precision medicine, supportive government genome initiatives, and partnerships between private diagnostic labs and academic research institutions.

India Next Generation Sequencing Market Statical Scope

Next-Generation Sequencing (NGS) is crucial for India as it reveals the vast genetic diversity among thousands of different population groups. This technology promotes personalized medicine, speeds up the diagnosis of rare diseases and cancer, and improves the tracking of infectious diseases specifically for the Indian population, rather than depending on Western genetic databases. Significant initiatives like the Genome India Project utilize NGS to identify millions of genetic markers that are unique to Indian groups.

It considers local population structures and marriage patterns that highlight specific genetic traits. It helps determine the exact frequency of disease-related mutations that are common in the area. It predicts how different groups process medications, reducing the risk of negative reactions to standard drugs or anesthesia. It accelerates the identification of hereditary disorders prevalent in local families. Additionally, it also helps in targeted cancer treatments by accurately analyzing tumor profiles.

India Next Generation Sequencing Market, By Product, 2025 (%)

• NGS Consumables - The consumables segment, with a share of 33.00% in 2025, for Next-Generation Sequencing (NGS) leads as it generates consistent, high-volume revenue. Reagents, kits, and flow cells are used up with each clinical test, cancer diagnostic panel, and research run. As genomic testing grows in India's clinical and academic labs, this ongoing demand creates a stable and expanding market.
• Sequencing Services - The sequencing services segment, with a share of 20.00% in 2025, plays a key role in India's NGS market by connecting high capital costs with clinical needs. Many regional hospitals, diagnostic labs, and academic institutions prefer to outsource complex genomic processes instead of investing in costly equipment and specialized bioinformatics teams.
• Presequencing Products & Services - The presequencing products and services segment, with a share of 13.00% in 2025, which includes sample preparation, library preparation, and target enrichment, is essential in India's NGS market. It directly drives data accuracy, manages low-quality clinical samples, minimizes expensive run failures, and processes a large volume of various oncology and infectious disease samples.

India Next Generation Sequencing Market, By Application, 2025 (%)

• Diagnostics - The diagnostics segment, with a share of 22.00% in 2025, is the largest and fastest-growing area in the Indian NGS market. It supports extensive clinical testing for oncology profiling, rare genetic disorders, reproductive health, and infectious disease monitoring, enabling doctors to provide accurate, personalized treatments as sequencing costs decrease.
• Biomarkers and Cancer - The biomarker and cancer segment, with a share of 21.00% in 2025, is a driving force in the India NGS market due to the significant rise in cancer cases. It helps in accurate tumor profiling and personalized therapy, moving away from outdated single-gene tests to advanced multi-gene analysis.

India Next Generation Sequencing Market, By Technology, 2025 (%)

• Whole Genome Sequencing (WGS) - The Whole Genome Sequencing (WGS), with a share of 27.00% in 2025, is crucial in India's Next Generation Sequencing (NGS) market as it supports large-scale public health projects, speeds up precision cancer treatment, the identification of rare genetic disorders, and takes advantage of growing local research facilities and lower costs.
• Sequencing by Synthesis - The Sequencing by Synthesis (SBS) segment, with a share of 31.00% in 2025, leads India's Next Generation Sequencing (NGS) market. This dominance is due to its exceptional base-calling accuracy, high-throughput capacity, and strong clinical and research validation, which support the country's growing oncology and precision medicine efforts.

India Next Generation Sequencing Market, By End-use, 2025 (%)

• Academic Research - The academic research sector, with a share of 27.00% in 2025, is crucial in the India Next Generation Sequencing (NGS) market, as it serves as the essential basis for foundational genomic studies, national disease monitoring, method validation, and talent cultivation, significantly supported by public funding and extensive population genome initiatives.
• Clinical Research - The clinical research sector, with a share of 19.00% in 2025, is vital in the India Next Generation Sequencing (NGS) market, driven by precision oncology, rapid identification of rare diseases, and aiding biomarker discovery for both local and international pharmaceutical trials. With decreasing sequencing costs, clinical processes are increasingly dependent on NGS to assess targeted therapies and identify various genetic variants specific to the Indian population.

Competitive Landscape

The Next Generation Sequencing (NGS) market in India is growing quickly, driven by increasing needs in cancer research, infectious diseases, and diagnosing rare conditions. The competitive landscape includes major global companies providing high-throughput equipment and reagents, along with local clinical and service labs that offer tailored genomic testing and interpretation.

• Illumina leads in hardware and platforms with a wide range of sequencers (like NovaSeq and desktop models) that are widely used in major research institutions in India.
• Thermo Fisher Scientific supplies Ion Torrent and capillary systems, which are commonly used for targeted cancer panels and microbial sequencing.
• Oxford Nanopore Technologies is making significant strides through partnerships in India, providing portable, real-time long-read sequencing with devices such as MinION and PromethION.
• Agilent Technologies offers essential tools for upstream workflows, including target enrichment kits, custom hybridization capture libraries, and automated sample preparation equipment.
• MedGenome is a top player in clinical genomics in India, focusing on advanced NGS diagnostics for cancer, reproductive health, and rare inherited diseases.
• Strand Life Sciences provides sophisticated genomic profiling, bioinformatics services, and clinical-grade NGS interpretation for personalized cancer therapies.
• Mapmygenome emphasizes personal genomics, wellness assessments, and specialized clinical diagnostic tests using high-throughput sequencing.
• Genotypic Technology is one of the first boutique genomics firms in India, offering extensive transcriptomics, whole-genome sequencing, and tailored NGS workflows for both academic and industrial applications.

Segments Covered in the Report

By Product

• NGS Consumables
• Sequencing Services
• Presequencing Products & Services
• NGS Platforms
• Bioinformatics
• Services for NGS Platforms

By Application

• Diagnostics
• Biomarkers and Cancer
• Reproductive Health
• Personalized Medicine
• Agriculture and Animal Research
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Consumer Genomics
• Others

By Technology

• Whole Genome Sequencing (WGS)
• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Sequencing by Ligation
• Pyrosequencing
• Single Molecule Real Time Sequencing
• Others

By Workflow

• Pre-Sequencing
• Sequencing
• NGS Data Analysis

By End-use

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other Users